These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 10703776)
1. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776 [TBL] [Abstract][Full Text] [Related]
2. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774 [TBL] [Abstract][Full Text] [Related]
3. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. Katzan IL; Furlan AJ; Lloyd LE; Frank JI; Harper DL; Hinchey JA; Hammel JP; Qu A; Sila CA JAMA; 2000 Mar; 283(9):1151-8. PubMed ID: 10703777 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke. Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399 [TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384 [TBL] [Abstract][Full Text] [Related]
6. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462 [TBL] [Abstract][Full Text] [Related]
8. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Ong CT; Wong YS; Wu CS; Su YH Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721 [TBL] [Abstract][Full Text] [Related]
9. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Toyoda K; Koga M; Naganuma M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Minematsu K; Stroke; 2009 Nov; 40(11):3591-5. PubMed ID: 19762694 [TBL] [Abstract][Full Text] [Related]
10. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152 [TBL] [Abstract][Full Text] [Related]
12. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Hsu YC; Sung SF; Ong CT; Wu CS; Su YH Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569 [TBL] [Abstract][Full Text] [Related]
13. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Tsivgoulis G; Saqqur M; Sharma VK; Lao AY; Hill MD; Alexandrov AV; Stroke; 2007 Mar; 38(3):961-6. PubMed ID: 17255548 [TBL] [Abstract][Full Text] [Related]
14. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Berrouschot J; Röther J; Glahn J; Kucinski T; Fiehler J; Thomalla G Stroke; 2005 Nov; 36(11):2421-5. PubMed ID: 16210554 [TBL] [Abstract][Full Text] [Related]
16. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Lewandowski CA; Frankel M; Tomsick TA; Broderick J; Frey J; Clark W; Starkman S; Grotta J; Spilker J; Khoury J; Brott T Stroke; 1999 Dec; 30(12):2598-605. PubMed ID: 10582984 [TBL] [Abstract][Full Text] [Related]
17. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort. Cronin CA; Langenberg P; Dutta TM; Kittner SJ Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551 [TBL] [Abstract][Full Text] [Related]
18. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260 [TBL] [Abstract][Full Text] [Related]
19. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke. Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI; Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860 [TBL] [Abstract][Full Text] [Related]
20. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. Saver JL; Fonarow GC; Smith EE; Reeves MJ; Grau-Sepulveda MV; Pan W; Olson DM; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2013 Jun; 309(23):2480-8. PubMed ID: 23780461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]